|  | Conditions & Treatments | Depression

Zulresso (Brexanolone): First FDA-Approved Treatment for Postpartum Depression

Breakthrough Approval

March 2019: FDA approved Zulresso (brexanolone) IV infusion – first drug specifically for postpartum depression (PPD). Prior: only general antidepressants used off-label.

Mechanism

Positive allosteric modulator of GABAA receptors (neurosteroid). Restores GABAergic tone disrupted by abrupt progesterone/allopregnanolone withdrawal postpartum. Rapid onset (hours–days) vs. weeks for SSRIs.

Clinical Profile

  • Indication: PPD in adults (≤6 mo postpartum, onset 3rd trimester–4 wks post-delivery).
  • Dosing: 60-hour continuous IV infusion in certified healthcare facility (REMS program). Titration: 30 → 60 → 90 µg/kg/hr (max).
  • Efficacy: Phase 3 (HUMMINGBIRD): Significant HAM-D reduction at 60 hrs vs. placebo; maintained Day 30.
  • Response rate: ~50–70% remission (HAM-D ≤7) vs. ~30–40% placebo.

Safety & Monitoring (REMS)

  • Sedation / loss of consciousness: Continuous pulse oximetry; 1:1 monitoring; caregiver present for infant.
  • Syncopal events: Hydration, slow titration.
  • Contraindicated: ESRD (CrCl <15), end-stage hepatic.
  • Breastfeeding: Low milk transfer; infant monitoring recommended. Decision shared.

Access & Practicalities

  • Certified sites only (hospitals, infusion centers).
  • Cost: ~$34,000/wholesale (2019); insurance coverage variable; patient support program.
  • Logistics: 2.5-day admission; arrange childcare, pump/store milk.

Zuranolone (Zurzuvae) – Oral Follow-On

August 2023: FDA approved zuranolone (Zurzuvae) – oral 50 mg nightly × 14 days. Similar mechanism (GABAA PAM). First oral PPD treatment. No REMS monitoring. Expands access dramatically.

Clinical Impact

  • Validates PPD as distinct neurobiological entity.
  • Rapid relief critical for mother-infant bonding, suicide prevention.
  • Highlights need: universal screening (EPDS), accessible treatment, stigma reduction.

Remaining Gaps

  • Long-term durability data.
  • Use in pregnancy (not studied).
  • Equitable access (rural, uninsured, minority populations).
  • Combination with psychotherapy – optimal sequencing.

Depression - Related Articles